Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BVC-210
- Development stage
- Preclinical
- Lead developer
- BioVinc
- Modality
- Small Molecules
- Administration
- Implant
01
Overview
BVC-210 is an antimicrobial bone graft material under development by BioVinc for the prevention and treatment of bone and implant-associated infections, such as osteomyelitis and peri-implantitis, in orthopedic and dental surgeries. The product utilizes BioVinc's bone-targeting platform, combining a bone graft substitute material with a bone-targeted bisphosphonate-conjugated antibiotic. This design allows for high-affinity binding to bone mineral (hydroxyapatite) and sustained local release of the active antimicrobial agent directly at the surgical site, overcoming the pharmacokinetic limitations and systemic toxicities associated with conventional systemic antibiotic therapies.
Beyond the preview
Go deeper on BVC-210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BVC-210.